Scientists have discovered an RNA-based mechanism that is involved in core hallmarks of a number of accelerated aging conditions and shown that therapies targeting this RNA reverses some of these hallmarks in human cells and extend life spans in mouse models.

Saniona has announced its program to develop small molecules targeting Kv7 ion channels to treat epilepsy has made sufficient progress to move into lead optimization.

During pregnancy, the female body experiments multiple physiological changes that require modulation of the neuroendocrine system, mainly being contributed by the hormone prolactin and its regulation by the hypothalamic tuberoinfundibular dopaminergic (TIDA) neurons.

International AIDS Vaccine Initiative (IAVI) and Merck & Co. scientists have developed a SARS-CoV-2 vaccine using the vesicular stomatitis virus (VSV) chimeric virus approach, wherein VSV was modified by substituting the VSV G surface glycoprotein gene with a coding sequence for the SARS-CoV-2 spike (S) glycoprotein.

Jingrui Biopharma has described bromodomain and extra-terminal (BET) inhibitors, particularly bromodomain-containing protein 4 (BD1 domain) (Brd4 BD1) inhibitors, reported to be useful for the treatment of cancer.

Medshine Discovery has disclosed pyrazolopyrazine-linked tricyclic compounds acting as tyrosine-protein phosphatase non-receptor type 11 (PTPN11) inhibitors reported to be useful for the treatment of cancer.

MagicMed Industries has divulged new prenylated psilocybin derivatives acting as 5-HT2A and/or 5-HT1A receptor modulators reported to be useful for the treatment of psychiatric disorders.

Metabrain Research and Shanghai Visonpharma have presented macrocyclic Toll-like receptor 7 (TLR7) agonists reported to be useful for the treatment of hepatitis B virus (HBV), HCV, HIV and influenza virus infections, and cancer.

Allorion Therapeutics has divulged imidazolopyridazines or pyrazolopyrimidines acting as nonreceptor tyrosine-protein kinase TYK2 inhibitors reported to be useful for the treatment of psoriasis, psoriatic arthritis, ulcerative colitis, Crohn's disease and systemic lupus erythematosus.

Live bacterial therapeutics (LBTs) that engraft in the gut and provide persistent beneficial functions to the host have emerged as a promising strategy against a wide range of diseases.